CAMBRIDGE, Mass. and GAITHERSBURG, Md., Jan. 4, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune announced that they have initiated a Phase 1b clinical trial of IPI-504 in combination with Taxotere(r) (docetaxel) in patients with advanced solid tumors. IPI-504, the companies' lead heat shock protein 90 (Hsp90) inhibitor, is currently in clinical development for a number of solid tumor cancers. Enrollment for this new study has commenced at Memorial Sloan-Kettering Cancer Center in New York, N.Y., with additional sites expected to be added as the study progresses.
